Clinical significance of combined detection of several biomarkers before and after radiotherapy in esophagus carcinoma
10.3760/cma.j.issn.1006-9801.2009.12.014
- VernacularTitle:食管癌放疗前后多种生物标志物联合检测的临床意义
- Author:
Jie LI
;
Jing WANG
;
Wenjing DU
;
Dan GUO
;
Jingyi WANG
;
Xia HOU
;
Baozhen ZHENG
- Publication Type:Journal Article
- Keywords:
Esophageal neoplasms;
Prognosis;
Radiotherapy;
computer-assisted;
CEA;
SCC;
CYFRA21-1
- From:
Cancer Research and Clinic
2009;21(12):837-839,842
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical significance of combined detection of serum CEA, SCC, CYFRA21-1 before and after radiotherapy in esophagus carcinoma. Methods 226 cases of esophagus carcinoma patient were collected from November, 2006 to December, 2008. ELISA was used to detect the serum CEA, SCC and CYFRA21-1 of patients with esophagus cancer before and after radiotherapy. SPSS13.0 was used for the statistical analysis. Results The positive rate of CEA, SCC and CYFRA21-1 was 11.1 %, 16.8%, 27.4 %, respectively and the combined positive rate was 39.8 % from 226 patient serums before radiotherapy. The longer the lesion length, the later the clinical stage,the deeper the tumor invasion, the higher the mean value of serum CEA, SCC, CYFRA21-1 was. The mean value was lower in the early stage. The mean value of CEA, SCC and CYFRA21-1 was found to be well correlated with tumor size, TNM stage and depth of tumor invasion. Among three tumor biomarkers, the individual difference of CEA and CYFRA21-1 was bigger and the pathological stage and prognosis correlation with CYFRA21-1 was the best. The biomarker value dropped to the level below the normal in 76.7% patient out of 90 cases after radiotherapy. Conclusion The combined detection of serum CEA, SCC, CYFRA21-1 may be used as adjuvant diagnosis for esophagus cancer and has better clinical value for prediction to treatment and prognosis.
